1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 11-15 of 15 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsTang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
2012Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with NilotinibBranford, S.; Kim, D.; Soverini, S.; Haque, A.; Shou, Y.; Woodman, R.; Kantarjian, H.; Martinelli, G.; Radich, J.; Saglio, G.; Hochhaus, A.; Hughes, T.; Muller, M.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.
2010Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with ImatinibWhite, D.; Dang, P.; Engler, J.; Frede, A.; Osborn, M.; Saunders, V.; Manley, P.; Zrim, S.; Hughes, T.
2017Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemiaBanjar, H.; Ranasinghe, D.; Brown, F.; Adelson, D.; Kroger, T.; Leclercq, T.; White, D.; Hughes, T.; Chaudhri, N.; Speletas, M.

Discover